Adoptive cell therapy (ACT) as an approach to cancer treatment involves the administration of antitumor immune cells to target residual disease in patients after completion of chemo/radiotherapy. Currently, the identification and generation of antitumor effector cells that efficiently recognize tumor cells remain important barriers to the success of ACT in cancer clinical trials.
The promotion of blood vessel growth for therapeutic purposes remains a challenge both for the treatment of ischemia and the generation of functional tissue‐engineered grafts, as physiological angiogenesis represents an extraordinarily complex process.
Three‐dimensional biofabrication using photo‐cross-linkable hydrogel bioscaffolds may revolutionize the need for transplants and implants in joints, with articular cartilage being an early target tissue.
A new review article from the laboratory of Åsa Ekblad‐Nordberg (Karolinska Institutet, Stockholm, Sweden) provides a summary of the past, the present progress, and the future potential of prenatal stem cell therapy.
While human pluripotent stem cells (hPSCs) provide an unprecedented opportunity to investigate human development and the relationship between gene regulation and differentiation, we currently lack a stable hPSC reporter line available for non-invasive fate mapping.
The Stem Cells Portal is a shared platform for the STEM CELLS and STEM CELLS Translational Medicine sister journals, providing up-to-the-minute coverage of the latest research from bench science and developments to clinical applications.